Skip to main content
. Author manuscript; available in PMC: 2013 May 15.
Published in final edited form as: Anal Chem. 2012 May 2;84(10):4618–4621. doi: 10.1021/ac300496q

Figure 3.

Figure 3

Performance of the multistage capture-release device system in dual-marker separation of EPCs from whole, untreated human blood. The target cells for these experiments were EPCs, which are CD34+ and Flk1+. The first capture stage is designed to selectively capture CD34+ cells. The second stage is designed to further enrich this population and remove CD34+ hematopoietic stem cells. The sample volume for each experiment was 300 μL of whole blood and numbers of cells in this figure are reported without any normalization. Cell counts were determined via flow cytometry. Error bars represent standard deviations based on 3 replicates.